p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Jurnal Inovasi Global
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Comparing Potassium-Competitive Acid Blocker And Proton Pump Inhibitor For Gastroeshopageal Reflux Disease: A Systematic Review And Meta-Analysis Narendra, Ida Bagus Putra
Jurnal Inovasi Global Vol. 3 No. 3 (2025): Jurnal Inovasi Global
Publisher : Riviera Publishing

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58344/jig.v3i3.294

Abstract

Clinical management is typically used to treat gastroesophageal reflux disease (GERD). Assessed individuals with a range of clinical symptoms of gastroesophageal reflux disease (GERD) to determine the safety and effectiveness of potassium-competitive acid blockers (PCABs). By examining core databases, studies comparing PCABs and proton pump inhibitors (PPIs) in clinical gastroesophageal reflux disease (GERD) and PPI-resistant GERD were identified. In nine randomized controlled trials (RCTs) evaluating the first care of GERD, the risk ratio for healing with PCABs versus PPIs was 1.09 (95% CI, 1.04-1.13) at 2 weeks and 1.03 (95% CI, 1.00-1.07) after 8 weeks, respectively. While 86.3% of PPI-resistant GERD patients reported an improvement in symptom frequency, 90.7% of patients showed improvement in five observational trials. When it comes to the initial and ongoing treatment of GERD, especially severe GERD, PCABs are more effective and have a quicker therapeutic effect than PPIs. However, PCABs might be a different kind of treatment for GERD and GERD that is resistant to PPIs.
Diagnosis Approach For Head of Pancreatic Carcinoma with Hepatitis B Narendra, Ida Bagus Putra; Made Suma Wirawan Wangaya, I
Jurnal Inovasi Global Vol. 3 No. 5 (2025): Jurnal Inovasi Global
Publisher : Riviera Publishing

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58344/jig.v3i5.329

Abstract

Pancreatic cancer is one of the deadliest malignant tumor with short overall survival, 3-5 months survival and 5 years 3% at an advanced stage. Pancreatic cancer is the fourth leading cause of cancer death globally according to Global Cancer Statistics 2024. Symptoms of pancreatic cancer are nonspecific in the early stages causing patients to come on at an advanced stage, which contributes to poor outcomes, decreased quality of life and shortened overall survival. A 35-year-old man came in with the main symptoms of abdominal swelling and jaundice from a month earlier. Symptoms are accompanied by sensations of a full abdomen, nausea and edema of both lower extremities. Eye examination shows pale conjunctiva and scleral jaundice, warm extremities and there is pitting edema in the pre-tibia region. Laboratory results showed anemia accompanied by an increase in direct bilirubin. The HbsAg test showed positive. Ultrasound examination showed the impression of obstructive jaundice with a suspected mass in the head of the pancreas. There is intrahepatic bile duct dilation (IHBD) (Figure 1) and extrahepatic bile duct (EHBD) features with mud and ascites features and abdominal CT scan shows masses in the head of the pancreas. Pancreatic carcinoma mostly occurs at the age of 60-80 years, 85% of patients have clinical symptoms of obstructive jaundice, pruritus, dark urine, and obstructive bile ducts. Symptoms of malignancy are associated with a gradual onset, weight loss, and are sometimes accompanied by abdominal pain. Bile obstruction can be caused by tumor, especially in the caput of the pancreas i.e. a slight increase in bilirubin levels, which spontaneously fall off without any intervention. In pancreatic cancer, bilirubin levels tend to rise when there is no intervention. Pancreatic caput cancer is relatively rare but has a high malignancy. It is possible that the inactive HBV-pancreatic cells then encode some functional proteins that induce local inflammation. HBV can trigger the proliferation and migration of pancreatic cancer cells. Making a diagnosis is often difficult because symptoms usually appear after the cancer has reached an advanced stage.